SOPH
NASDAQSOPHiA GENETICS SA
Price$5.25+0.34 (+6.92%)
2026-03-192026-06-23
News · 26 weeks138+44%
2025-12-282026-06-21
Mix9790d
- Insider74(76%)
- SEC Filings13(13%)
- Offering5(5%)
- Other3(3%)
- Earnings2(2%)
Latest news
25 items- INSIDERChief Financial Officer Cardoza George sold $4,164 worth of Ordinary Shares (774 units at $5.38) as part of a pre-agreed trading plan, decreasing direct ownership by 0.25% to 310,684 units (SEC Form 4) to satisfy withholding obligation4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERPresident Muken Ross sold $2,270 worth of Ordinary Shares (422 units at $5.38) as part of a pre-agreed trading plan, decreasing direct ownership by 0.06% to 680,489 units (SEC Form 4) (for withholding tax)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- SECSEC Form 144 filed by SOPHiA GENETICS SA144 - SOPHiA GENETICS SA (0001840706) (Subject)
- INSIDERDirector Cox Troy was granted 19,724 units of Ordinary Shares, increasing direct ownership by 6% to 328,743 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERDirector Ossipow Vincent was granted 19,724 units of Ordinary Shares, increasing direct ownership by 4% to 522,860 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERDirector Hibbs Kathy L was granted 19,724 units of Ordinary Shares, increasing direct ownership by 22% to 109,492 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERDirector Hirsch Didier was granted 19,724 units of Ordinary Shares, increasing direct ownership by 9% to 240,220 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERDirector Cossery Jean-Michel was granted 19,724 units of Ordinary Shares, increasing direct ownership by 11% to 206,212 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- SECSEC Form 6-K filed by SOPHiA GENETICS SA6-K - SOPHiA GENETICS SA (0001840706) (Filer)
- PRSOPHiA GENETICS Publishes Results of the 2026 Annual General MeetingShareholders adopt all proposals, co-founder Dr. Jurgi Camblong elected as Executive Chairman of the Board, Ross Muken elected as new member of the Board ahead of his appointment as CEO effective July 1, 2026ROLLE, Switzerland, June 22, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in Ai-driven precision medicine, today announced that its 2026 Annual General Meeting of shareholders adopted all proposals on the agenda, electing Dr. Jurgi Camblong as the Executive Chairman of the Board of Directors with 99.79% of the votes, and Ross Muken as a member of the Board of Directors for the first time with 99.88% of the votes. Mr. Muken will assume the role of Chief Executive Of
- SECSEC Form 6-K filed by SOPHiA GENETICS SA6-K - SOPHiA GENETICS SA (0001840706) (Filer)
- PRSOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional SharesBOSTON and ROLLE, Switzerland, June 19, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in Ai-driven precision medicine, announced today the closing of its previously announced underwritten public offering with total gross proceeds of $57.5 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company. As a result of strong investor demand, the offering was oversubscribed, and the underwriters fully exercised their option to purchase an additional 1,578,900 ordinary shares at the public offering price, less the underwriting discounts and commissions. The Company sold 12,104,900 ordinary shares at a price to the
- SECSEC Form 424B5 filed by SOPHiA GENETICS SA424B5 - SOPHiA GENETICS SA (0001840706) (Filer)
- INSIDERChief Scientific Officer Xu Zhenyu sold $20,056 worth of Ordinary Shares (4,000 units at $5.01) as part of a pre-agreed trading plan, decreasing direct ownership by 0.64% to 622,280 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- PRSOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary SharesBOSTON and ROLLE, Switzerland, June 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in Ai-driven precision medicine, announced today the pricing of its previously announced underwritten public offering of 10,526,000 ordinary shares at a public offering price of $4.75 per ordinary share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company are expected to be approximately $50 million. All of the ordinary shares to be sold in the proposed offering will be sold by the Company. In addition, the Company has granted the underwriters a 30-day option to purchase up to 1,578,900
- SECSEC Form 424B5 filed by SOPHiA GENETICS SA424B5 - SOPHiA GENETICS SA (0001840706) (Filer)
- PRSOPHiA GENETICS Announces Proposed Public Offering of Ordinary SharesBOSTON and ROLLE, Switzerland, June 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in Ai-driven precision medicine, announced today the commencement of a proposed underwritten public offering of its ordinary shares. The Company also expects to grant the underwriters an option to purchase up to an additional 15% of the ordinary shares at the public offering price, less the underwriting discount. All of the ordinary shares to be sold in the proposed offering will be sold by the Company. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offer
- INSIDERChief Medical Officer Menu Philippe sold $24,752 worth of Ordinary Shares (5,000 units at $4.95) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 245,780 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- PRSOPHiA GENETICS Confirms Leadership Transition Ahead of 2026 Annual General MeetingRoss Muken to assume the role of Chief Executive Officer effective July 1, 2026; Co-founder Dr. Jurgi Camblong nominated for election as Chairman of the BoardBOSTON and ROLLE, Switzerland, June 10, 2026 /CNW/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in Ai-driven precision medicine, today confirmed, ahead of its 2026 Annual General Meeting (AGM) scheduled for June 18, 2026, the leadership changes first announced in January 2026. The Board has appointed Ross Muken, currently President, as Chief Executive Officer, effective July 1, 2026, and nominated him for election as a member of the Board of Directors. Furthermore, as
- INSIDERChief Financial Officer Cardoza George bought $99,000 worth of Ordinary Shares (20,000 units at $4.95), increasing direct ownership by 7% to 311,458 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- SECSEC Form 6-K filed by SOPHiA GENETICS SA6-K - SOPHiA GENETICS SA (0001840706) (Filer)
- PRSOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer CenterSOPHiA GENETICS and Memorial Sloan Kettering Cancer Center Aim to Establish Precision Medicine Hub for the Next Generation of Precision OncologyNEW YORK, June 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH) today announced that the company has signed a Memorandum of Understanding (MOU) with Memorial Sloan Kettering Cancer Center (MSK) relating to the formation of a joint venture between the two institutions. The joint venture aims to build upon the strength of MSK innovation in clinical diagnostics and SOPHiA GENETICS's Ai platform to potentially discover, develop, and deploy a new generation of precision oncology to patients around the world.
- INSIDERChief Medical Officer Menu Philippe sold $24,774 worth of Ordinary Shares (5,000 units at $4.95) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 250,780 units (SEC Form 4)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERPresident Muken Ross sold $3,501 worth of Ordinary Shares (761 units at $4.60) as part of a pre-agreed trading plan, decreasing direct ownership by 0.11% to 680,911 units (SEC Form 4) (tax liability)4 - SOPHiA GENETICS SA (0001840706) (Issuer)
- INSIDERChief Scientific Officer Xu Zhenyu sold $2,798 worth of Ordinary Shares (608 units at $4.60) as part of a pre-agreed trading plan, decreasing direct ownership by 0.10% to 626,280 units (SEC Form 4) to satisfy tax liability4 - SOPHiA GENETICS SA (0001840706) (Issuer)
SOPH FAQ
7 questionsWhat does SOPHiA GENETICS SA do?
Sophia Genetics SA, a cloud-based software-as-a-service platform that enables healthcare institutions to get insights from their data. The company offers SOPHiA DDM for solid tumors. Sophia Genetics SA was founded in 2012 and is based in Saint-Sulpice, Switzerland.Where does SOPH stock trade?
SOPHiA GENETICS SA (SOPH) is listed on NASDAQ.What sector and industry is SOPH in?
SOPHiA GENETICS SA operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did SOPHiA GENETICS SA go public?
SOPHiA GENETICS SA (SOPH) completed its IPO in 2021.What are analysts saying about SOPH?
SOPHiA GENETICS SA has had 8 recent analyst actions on file. The most recent action was from Craig Hallum: Buy with a $1100.00 price target on 2024-12-18.What companies are similar to SOPH?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare SOPH side-by-side with any of them on Quantisnow.How can I track SOPH on Quantisnow?
Quantisnow aggregates SOPHiA GENETICS SA's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SOPH to receive live email and push alerts on every new disclosure.